{
    "nctId": "NCT01956747",
    "briefTitle": "Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies",
    "officialTitle": "Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Colorectum Advanced Malignancies, Breast Advanced Malignancies, Prostate Advanced Malignancies",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "To determine whether the presence of a low - intermediate 1 risk MDS, IDUS or ICUS can predict for (myelo)toxicity in older patients with advanced malignancies receiving palliative chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 70 years\n* Diagnosis of advanced cancer of colorectum, breast or prostate\n* Standard first line palliative treatment with cytotoxic agents will be started (Folfox, Xelox, capecitabine, paclitaxel or docetaxel)\n* Estimated life expectancy \u2265 3 months\n* Able to give informed consent\n* WHO performance status \u2264 2\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the treatment and follow-up schedule; those conditions should be assessed with the patient before registration in the trial\n* No other severe medical or psychiatric conditions that in the judgment of the investigator renders the patient inappropriate for inclusion in this study.\n* Before patient registration, written informed consent must be given and documented to ICH/EUCGCP, national/local regulatory requirements and the local rules followed in our institution\n\nExclusion Criteria:\n\n* Presence of cytopenia due to iron-, vitamin B12 and folic acid deficiency or hemolysis, unless adequately supplemented.\n* Creatinine clearance \u2264 30 ml/min\n* Serum AST and ALT \u2265 2.5 x ULN, in case of liver metastases serum AST and ALT \u2265 5 x ULN\n* In case of therapy with Docetaxel/Paclitaxel serum bilirubin \u2265 1.5 x ULN",
    "sex": "ALL",
    "minimumAge": "70 Years",
    "stdAges": "OLDER_ADULT"
}